Hello all,
Interesting to see, no post in last one year, whereas the company is doing quite well. Growth has been good, recent acquisition of “PatientMatters LLC” in USA ( cost: 96 crs, funded through internal accruals ) is going to help company consolidate its leadership position in USA health segment.
Look at the ,cash flow, 9 month FY21 cash flow from operation is 160%+ of the Full year FY20 cash flow, thats huge. ( 3 Rs interim dividend in Feb 2021, that itself is 1% dividend yield, going to be much more for full year).
Overall, I see the business to scale up rapidly, with profitability improving, strong cash flow and debt reduction and these should help stock price appreciate.
Thanks,
Hafizul
Disc- invested.